Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms

Magdalena Czader, Attilio Orazi

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

OBJECTIVES: This session of the Society for Hematopathology/European Association for Haematopathology workshop focused on disease progression in myeloproliferative neoplasms (MPNs).

METHODS: The session included typical and unusual presentations of chronic myelogenous leukemia (CML), BCR-ABL1 positive; Philadelphia chromosome-negative (Ph-neg) MPNs; and mastocytosis.

RESULTS: Cases of CML illustrated various manifestations of progression, with emphasis on criteria defining stages of the disease. Issues were discussed related to the patterns of recurrence in patients receiving tyrosine kinase inhibitor therapy, including leukemic transformation occurring in a Ph-neg clone. Ph-neg MPN cases highlighted diagnostic approaches used to establish accelerated and blast phases, including cases with significant myelofibrosis and when an adequate bone marrow aspirate smear is not available. The session also included rare cases of aggressive mastocytosis.

CONCLUSIONS: There was agreement that a definitive diagnosis can be challenging in the absence of documented review of prior diagnostic material and clinical history.

Original languageEnglish (US)
Pages (from-to)188-206
Number of pages19
JournalAmerican journal of clinical pathology
Volume144
Issue number2
DOIs
StatePublished - Aug 2015

Keywords

  • Accelerated phase
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • BCR-ABL1 positive
  • Blast phase
  • Chronic myelogenous leukemia
  • Chronic neutrophilic leukemia
  • Essential thrombocythemia
  • Myelodysplastic syndromes
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Primary myelofibrosis
  • Progression
  • Systemic mastocytosis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms'. Together they form a unique fingerprint.

  • Cite this